COX-2s Lose Favor












Initially hailed as breakthrough medications, COX-2 inhibitors have steadily lost formulary status over the past 12 months, according to data compiled by Formulary Compass. Questions about their relative efficacy and side effects, cardiovascular toxicity in particular, may have contributed to reduced coverage in lower tiers.

Comparing first quarter 2002 with first quarter 2003, Celebrex (celecoxib), the first of the COX-2 agents launched in the U.S., dropped from 26 percent of covered lives on approved, Tier 1 or Tier 2 status to only 18.7 percent. From March 2002 to March 2003, prior authorization status for celecoxib climbed from 36 percent of covered lives to 44 percent (Figure 1).

Similar data are seen with Vioxx (rofecoxib) during this time frame. Approved, Tier 1 or Tier 2 status dropped from 28.8 percent of covered lives to 17.5 percent for the second COX-2 launched in the U.S. Prior authorization status rose during this time, from 37.1 percent to 43.6 percent (Figure 2).

Does this trend apply to the most recently launched COX-2 inhibitor, Bextra (valdecoxib)? With a year under its belt, valdecoxib is experiencing an increase in prior authorizations — up from 30.1 percent in March 2002 to 38.2 percent one year later (Figure 3).

This information comes from Formulary Compass, MediMedia USA's regularly updated database of approximately 3,000 managed care formularies.

SOURCE: MEDIMEDIA INFORMATION TECHNOLOGIES

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA

Subscribe to Our Newsletters

Monthly table of contents

Be notified as each issue of Managed Care is available online.

Biweekly newsletter

Recent topics have included:

PTCommunity news

New drug approvals, clinical trials, drug management. Three times per week.

UP NEXT

Managed Care
By Peter Wehrwein
Managed Care
By Howard Wolinsky